Johnson & Johnson joins Merck, others, in fighting Medicare drug-price program

Johnson & Johnson
JNJ,
-0.01%
has joined companies such as Merck & Co. Inc.
MRK,
+0.36%,
Bristol Myers Squibb Co.
BMY,
+0.24%
and other entities in suing the federal government over Medicare’s drug-price negotiation program. Merck was first with its suit in June, alleging that the plan is a scheme to allow Medicare to obtain prescription drugs without paying fair market value, a contention the Biden administration has decried. Shares of Johnson & Johnson edged higher in the aftermarket Tuesday after ending the regular trading day flat.